Even when it is reported that nearly 20% of patients with MDS del(5q) harbor TP53 mutations [18], Scharenberg et al. suggested that, in some cases, this mutation is acquired during the disease evolution, especially after lenalidomide treatment [36]. Here, TP53 is linked to myelodysplastic syndrome.